Cytomegalovirus (CMV) Infection Clinical Trial Pipeline Analysis: 15+ Key Companies Shaping the Future of CMV Infection Therapeutics | DelveInsight

DelveInsight's Cytomegalovirus (CMV) Infection Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline CMV Infection therapies in various stages of clinical development. The report covers 15+ companies and 20+ pipeline drugs, providing insights into clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the CMV Infection Clinical Trial Landscape Report

• DelveInsight's CMV Infection pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for CMV Infection treatment.
• Key CMV Infection companies such as ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, EVAXION BIOTECH A/S, and others.
• Promising CMV Infection pipeline therapies in various stages of development include mRNA-1647, Cytomegalovirus vaccine (Triplex), VBI-1501, SPYVAC01, VIR-1388|Placebo, GSK3993129, and EVX-V1.

Request a sample and discover the recent advances in CMV Infection treatment drugs https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Cytomegalovirus (CMV) Infection?

Cytomegalovirus (CMV) is a common virus belonging to the herpesvirus family that often causes asymptomatic infections in healthy individuals. However, it can be severe in immunocompromised patients and can cause congenital infections, potentially resulting in long-term complications such as hearing loss and developmental disabilities.
Following primary infection, CMV establishes latency in myeloid cells, where it remains dormant for the host's lifetime. The immune system, particularly cytotoxic T-cells, plays an important role in controlling viral replication and reactivation. When the immune system is compromised, CMV can reactivate and cause symptoms ranging from mild to life-threatening.
CMV Infection can be diagnosed through blood, saliva, urine, and tissue samples. PCR testing of saliva is commonly used for diagnosing congenital CMV infection in newborns. Treatment options include antiviral agents such as cidofovir, foscarnet, ganciclovir, and valganciclovir, although their use can be associated with toxicity and side effects.

Emerging CMV Infection Drug Profiles

mRNA-1647: ModernaTX, Inc.
mRNA-1647 comprises six mRNAs encoding two antigens in one vaccine and is designed to protect against CMV infection. Five mRNAs encode the subunits of the CMV pentamer complex, while one mRNA encodes the glycoprotein B (gB) protein. The vaccine is designed to generate an immune response against both antigens, with the potential to prevent CMV entry into a range of target cell types and prevent primary and congenital infections. Currently, mRNA-1647 is in Phase II development for CMV Infection.

Cytomegalovirus vaccine (Triplex): Helocyte
The Triplex vaccine by Helocyte is a multi-antigen vaccine designed to induce a robust and durable virus-specific T-cell response against CMV infections, particularly in recipients of allogeneic hematopoietic stem cell transplants and solid organ transplants. The vaccine uses a Modified Vaccinia Ankara (MVA) vector to express three immunodominant CMV proteins: UL83 (pp65), UL123 (IE1), and UL122 (IE2). Currently, the vaccine is in Phase II development for CMV Infection.

VBI-1501: VBI Vaccines Inc.
VBI-1501 is a prophylactic CMV vaccine candidate developed using VBI Vaccines Inc.'s proprietary enveloped virus-like particle (eVLP) technology. The vaccine presents a modified form of the CMV glycoprotein B (gB), which plays an important role in viral entry into host cells. VBI-1501 is designed to induce protective CMV-neutralizing antibodies that can block infection in multiple cell types. Currently, the drug is in Phase I development for CMV Infection.

Learn more about the novel and emerging CMV Infection pipeline therapies https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the CMV Infection Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key CMV Infection Companies: ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, EVAXION BIOTECH A/S
• Key CMV Infection Pipeline Therapies: mRNA-1647, Cytomegalovirus vaccine (Triplex), VBI-1501, SPYVAC01, VIR-1388|Placebo, GSK3993129, EVX-V1

Dive deep into rich insights for new drugs for CMV Infection treatment, visit https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. CMV Infection Pipeline Report Introduction
2. CMV Infection Pipeline Report Executive Summary
3. CMV Infection Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. CMV Infection Pipeline Therapeutics
6. CMV Infection Pipeline: Late Stage Products (Phase III)
7. CMV Infection Pipeline: Mid Stage Products (Phase II)
8. CMV Infection Pipeline: Early Stage Products (Phase I)
9. CMV Infection Pipeline: Preclinical and Discovery Stage Products
10. CMV Infection Pipeline Therapeutics Assessment
11. Inactive Products in the CMV Infection Pipeline
12. Key Companies
13. Key Products in the CMV Infection Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the CMV Infection pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.